IONIS FXI LRX

Drug Profile

IONIS FXI LRX

Alternative Names: IONIS-FXI-LRX

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Antisense elements
  • Mechanism of Action Factor XI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Thrombosis

Most Recent Events

  • 14 Feb 2017 Preclinical trials in Thrombosis (Prevention) in USA (unspecified route) (Ionis Pharmaceuticals 8-K, February 2017)
  • 14 Feb 2017 IONIS FXI LRX licensed to Bayer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top